Skip to main content

SWI/SNF-deficient Malignancies: Optimal Candidates for Immune-oncological Therapy?

Buy Article:

$57.00 + tax (Refund Policy)

Inactivation of different subunits of the SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex has emerged as one of the most frequent genetic pathways driving a variety of neoplasms of diverse histogenesis, originating in different organs. With few exceptions, most SWI/SNF-deficient malignancies pursue a highly aggressive clinical course resulting in widespread disease dissemination either at or soon after diagnosis, ultimately causing patients’ death soon after diagnosis, despite the apparently curative treatment intention. To date, no satisfactorily effective systemic chemotherapy has been established for treating these diseases. This disappointing finding underlines the urgent need for an effective systemic therapy that would enable sufficient intermediate to long-term disease control. Recently, SWI/SNF-deficiency has increasingly emerged as pivotal in cancer immunogenicity and hence a promising biomarker predicting response to immune-checkpoint inhibition therapy utilizing several recently established drugs. This review summarizes the most recent literature on this topic with emphasis on the entities that most likely represent suitable candidates for immune therapy.

Keywords: ARID1A; PDL-1; SMARCA4; SMARCB1; SWI/SNF complex; epithelioid sarcoma; immune therapy; rhabdoid tumor

Document Type: Research Article

Affiliations: Institute of Pathology, Friedrich-Alexander University Erlangen-N├╝rnberg (FAU), Erlangen, Germany

Publication date: May 21, 2023

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content